A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Study Number
3655023
Phase
I
Age Group
Adult
Principal Investigator
Christos Fountzilas
Purpose

The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161.

Check your eligibility for this trial
Check now
Full Title

A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors ( IDE161-001)

ClinicalTrials.Gov ID
NCT05787587

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.